To further elucidate the molecular basis underlying decursin’s anti-tumor effects, we examined two malignancy-associated proteins (TP63 and SOX-2) under varying treatment durations (0 h, 24 h, 48 h, and 72 h) and concentrations (0 μM, 10 μM, 20 μM, and 40 μM). The gene discussed is TP63; the disease is neoplasm.